As part of this new sponsored research, the Narendran team plans to: Identify clinically-feasible drug combinations and synthetic lethality that have synergistic activity with Provectus' rose bengal, Evaluate systemic drug administration routes for maximal tolerability, Evaluate the modulation of WNK1 (lysine deficient protein kinase 1) and other related pathways induced by the Company's rose bengal, and Complete demonstration of
The Narendran team has previously shown: In vitro activity and target modulation effects of Provectus' rose bengal against several different pediatric leukemia?derived cell lines and primary cells, Proof?of-concept of several potential mechanisms that may be involved in this process, Rose bengal's ability to induce
About Provectus
Provectus' drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), animal health, and tissue regeneration and repair, and use multiple routes of administration, such as intralesional (IL), topical (.top), oral (P.O.), inhaled (.inh), intranasal (IN), and intravenous (IV).
Information about the Company's clinical trials can be found at the
FORWARD-LOOKING STATEMENTS:
The information in this press release may include 'forward-looking statements,' within the meaning of
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Contact:
CPA
Chief Financial Officer
Phone: 866-594-5999
(C) 2022 Electronic News Publishing, source